Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RegenerEyes in Dry Eye Treatment
NCT05169931Phase 1Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Injectable Hydrogels, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of RegenerEyes Ophthalmic Solution in dry eye disease (DED), sponsored by University of California, Los Angeles. Primary endpoint: Ocular Surface Disease Index at 12 weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
RegenerEyes Ophthalmic Solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05169931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169931.